SCHEMBL6359686

SCHEMBL6359686

O=C(CCN1CCN(c2ccccn2)CC1)c1ccc(Cl)cc1Cl

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 11/20 0.70
HTR1A P08908 2/20 0.64
KMT2A Q03164 2/20 0.61
HSD17B10 Q99714 2/20 0.57
DRD2 P14416 3/20 0.56
KDM4E B2RXH2 2/20 0.55
ALDH1A1 P00352 1/20 0.55
LMNA P02545 1/20 0.55
MAPT P10636 1/20 0.55
HPGD P15428 1/20 0.55
TSHR P16473 1/20 0.55
MAPK1 P28482 1/20 0.55
HTR7 P34969 2/20 0.54
MEN1 O00255 1/20 0.54
POLB P06746 1/20 0.54
EPHX2 P34913 1/20 0.54
HTR2A P28223 1/20 0.53
HTR2C P28335 1/20 0.53
DRD3 P35462 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6359334 0.90 KMT2A (0.67) DRD4HTR1AKMT2AHSD17B10KDM4E
SCHEMBL6350153 0.89 DRD4 (0.71) DRD4HTR1AKMT2AHSD17B10DRD2
SCHEMBL6351426 0.84 HTR1A (0.81) DRD4HTR1ADRD2LMNAHTR7
SCHEMBL6351568 0.83 HTR1A (0.76) DRD4HTR1ADRD2ALDH1A1LMNA
SCHEMBL6348959 0.82 DRD4 (1.00) DRD4DRD2
SCHEMBL6348965 0.82 DRD4 (1.00) DRD4DRD2
SCHEMBL6353149 0.82 DRD4 (1.00) DRD4DRD2
SCHEMBL6350278 0.81 HTR1A (0.72) DRD4HTR1ADRD2LMNAHTR7
SCHEMBL6359359 0.81 DRD4 (0.69) DRD4HTR1ADRD2LMNAHTR7
SCHEMBL6352654 0.79 DRD4 (0.71) DRD4HTR1AKMT2ADRD2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050176727-A1 Oximes and hydrazones that are useful in treating sexual dysfunction ABBOTT LABORATORIES 2005-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176727-A1 Oximes and hydrazones that are useful in treating sexual dysfunction CYP19A1, SHBG, CYP17A1 DRD4 1272/4885HTR1A 871/4885KMT2A 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.